Open AccessComparative evaluation of bone marrow cells morpho-functional activity in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors of the first and second generation
Author(s) -
I. O. Zhaleyko,
Denys bilko,
Irina Dyagil,
Nadiia Bilko
Publication year - 2014
Publication title -
vìsnik dnìpropetrovs'kogo unìversitetu. bìologìâ, medicina/vìsnik dnìpropetrovsʹkogo unìversitetu. serìâ bìologìâ, medicina
Language(s) - English
Resource type - Journals
eISSN - 2312-7295
pISSN - 2310-4155
DOI - 10.15421/021420
Subject(s) - nilotinib , tyrosine kinase , imatinib , medicine , myeloid leukemia , clone (java method) , cancer research , haematopoiesis , bone marrow , tyrosine kinase inhibitor , immunology , stem cell , biology , receptor , cancer , microbiology and biotechnology , biochemistry , dna
The efficiency of using the culture techniques of research for monitoring the patient’s response to the treatment by tyrosine kinase inhibitors of the first and second generation is shown. Thus, the functional activity of bone marrow cells in patients having the optimal treatment response to inhibitors of tyrosine kinases was significantly lower compared with patients with the acquired resistance to the drug, and patients who had CML diagnosed for first time. Furthermore, for patients with the optimal response to the nilotinib therapy, numbers of colonies in semi-solid agar in vitro was lower, than in patients with the optimal response to imatinib. When the leukaemic cell clone becomes resistant to tyrosine kinase inhibitors, the prevalence of early cells of granulocyte-macrophage hematopoietic stem cells is observed in CFU culture which can be an important prognostic factor for choosing the appropriate treatment strategy.